Bastian Schrader

Background: Lipoprotein(a) [Lp(a)] is a known independent risk factor for cardiovascular disease, yet awareness and management remain limited. The psychosocial implications of elevated Lp(a)-levels have been poorly characterized. Objectives: To compare cardiovascular outcomes and cardiovascular risk factor (CVRF) modification in individuals with normal vs. elevated Lp(a) levels, and to assess the impact of individualized prevention recommendations. For the first time, the individual psychological stress caused by Lp(a) is being surveyed. Methods: The ELITE study is a prospective, interventional cohort study conducted in north-western Germany. Participants were regularly assessed for CVRFs, including Lp(a), hypertension, dyslipidemia, diabetes mellitus, weight, nicotine – as well as lipoprotein (a), physical activity, dietary habits, depression and stress. They received written, personalized prevention recommendations. Follow-up averaged 4.4 years. Two groups were analyzed: Group 1 (Gr1, n=3,241) with normal Lp(a), and Group 2 (Gr2, n=841) with elevated Lp(a ≥75 nmol/l). Results: Gr2 (mean Lp(a) 154.8 nmol/l) and Gr1 (mean Lp(a) 16.4 nmol/l) were comparable in age (~53 years) and sex distribution (~49% female). Most participants with elevated Lp(a) were previously unaware of their levels; 30% were referred to specialists, and ~40% reported concern or anxiety. Combined cardiovascular endpoints (CHD, stroke, heart failure, PAD, carotid stenosis, AF) occurred significantly more often in Gr2 (p<0.001), despite similar CVRF profiles, except for higher baseline LDL-C in Gr2 (p<0.001). Hypertension (61%) and physical inactivity (57%) were the most prevalent CVRFs. Personalized prevention measures led to significant improvements in blood pressure, LDL-C, smoking, physical activity, and weight in both groups. Lipid-lowering therapy improved markedly in Gr2 (12% to 23%). Conclusions: Elevated Lp(a) is associated with a significantly higher rate of cardiovascular events, independent of traditional CVRFs. This confirms a causal role of Lp(a) in CV morbidity. Personalized written prevention recommendations improved CVRFs across both groups, though further optimization is needed. Notably, elevated Lp(a) also imposes a psychosocial burden, underlining the need for enhanced education, counseling, and clinical pathways.

Background: This prospective cohort study examines the association between hyperuricemia (HU) and cardiovascular diseases. The aim of the current study was to assess whether there might be a correlation between hyperuricemia and cardiovascular risk and future cardiovascular events. Methods: We analyzed data from 4082 participants, dividing them into two groups based on serum uric acid levels. Results: Our findings reveal that participants with elevated serum uric acid or xanthine oxidase inhibitor (XOI) therapy had a significantly higher incidence of cardiovascular events such as coronary artery disease (8.4% vs. 3.3%), stroke (2.6% vs. 1.2%), heart failure (3.4% vs. 0.9%), and chronic kidney insufficiency (4.5% vs. 1.9%) compared to those with normal uric acid levels. Moreover, group 2, which had higher serum uric acid levels, also exhibited a higher burden of established cardiovascular risk factors, including hypertension, obesity, and diabetes. These results support the hypothesis that HU is not only a marker for metabolic dysfunction but may also serve as an independent risk factor for cardiovascular morbidity and mortality. Conclusions: We propose that routine measurement of uric acid levels could be a valuable tool for early identification of high-risk cardiovascular patients, particularly in individuals with multiple metabolic risk factors. Further prospective studies are needed to explore the potential benefits of early XOI therapy in reducing cardiovascular events.

Objectives: To evaluate the prevalence, classification, and clinical relevance of incidental extracardiovascular findings in pre-transcatheter aortic valve implantation (TAVI) CT imaging. Methods: We conducted a retrospective single-center study of 225 patients undergoing pre-TAVI contrast-enhanced, ECG-gated CT scans between 2021 and 2023. Extracardiovascular findings were recorded and categorized into three groups based on presumed clinical relevance: Group A (findings with no need for follow-up), Group B (findings requiring follow-up), and Group C (findings requiring immediate intervention or treatment). Statistical analysis included a descriptive assessment of the overall prevalence of incidental findings and evaluation of age- and sex-related trends using chi-square tests with Bonferroni-adjusted pairwise comparisons. Results: The study cohort included 225 patients (53.3% male; mean age 79.9 ± 6.2 years, range 58–93). Extracardiovascular incidental findings were detected in 205 patients (91.1%). Among all 478 recorded findings, 82.6% were Group A, 14.4% Group B, and 2.9% Group C. On a per-patient level, 87.1% had at least one Group A finding, 24.9% had at least one Group B, and 6.2% had at least one Group C finding. Older age was associated with more incidental findings, with a significant difference observed between the 70–79 and 80–89 age groups (p = 0.002). No significant sex-related differences were found (p = 0.226). Findings were most frequently located in the abdomen (46.2%) and thorax (37.2%). Among all clinically relevant findings, the thorax was the most commonly affected region: 43.5% of Group B and 78.6% of Group C findings were located in the thorax, followed by the abdomen (33.3% of Group B and 7.1% of Group C findings). Conclusions: Extracardiovascular incidental findings are highly prevalent in pre-TAVI CT imaging and range from benign, age-related changes to potentially serious conditions such as malignancies or infections. Their presence reflects the comorbidity burden of the typical TAVI population and underscores the importance of recognizing non-vascular incidental findings in this clinical setting.

This prospective cohort study examines the association between hyperuricemia (HU) and cardiovascular diseases. We analyzed data from 4,082 participants, dividing them into two groups based on serum uric acid levels. Our findings reveal that participants with elevated serum uric acid or xanthine oxidase inhibitor (XOI) therapy had a significantly higher incidence of cardiovascular events such as coronary artery disease (8.4% vs 3.3%), stroke (2.6% vs. 1.2%), heart failure (3.4% vs. 0.9%), and chronic kidney insufficiency (4.5% vs. 1.9%) compared to those with normal uric acid levels. Moreover, group 2, which had higher serum uric acid levels, also exhibited a higher burden of established cardiovascular risk factors, including hypertension, obesity, and diabetes. These results support the hypothesis that HU is not only a marker for metabolic dysfunction but may also serve as an independent risk factor for cardiovascular morbidity and mortality. We propose that routine measurement of uric acid levels could be a valuable tool for early identification of high-risk cardiovascular patients, particularly in individuals with multiple metabolic risk factors. Further prospective studies are needed to explore the potential benefits of early XOI therapy in reducing cardiovascular events.

Aims: The MY-3F [Fit & Fun with Football after myocardial infarction (MI) or coronary artery disease (CAD)] study was the first to investigate whether a structured and health-adapted football training programme can improve fitness and risk factors in patients with CAD and whether it is safe. The primary objective of this study was to improve fitness in maximum oxygen uptake in spiroergometry (VO2peak), blood pressure, weight, and safety. Methods and results: The MY-3F study is a prospective randomized interventional study with 1-year follow-up in patients with MI or CAD. A football group (FG, n = 89) completed a structured ‘health’ football training (1 h/week, 75 min) led by licensed football coaches. The results were compared with a control group (CG, n = 88). VO2peak in the FG significantly increased from 18.0 to 19.7 mL/min/kg (P < 0.001), and VO2peak in the CG significantly decreased from 19.5 to 18.3 mL/min/kg (P = 0.046). In the FG, running performance per participant per training improved from 1.8 km at admission to 2.4 km at the end of study (P < 0.001). In the FG, blood pressure decreased from 132/81 to 125/76 mmHg (P < 0.001). In the CG, it changed slightly from 137/82 to 136/82 mmHg (ns). In addition, a significantly more antihypertensives were given in CG, but not in FB. In the FG, weight decreased from 92.3 to 90.4 kg (P = 0.003). In the CG, it increased slightly from 90.7 to 91 kg (P = 0.6 ns). Depressive symptoms showed a significant improvement in the FG (P = 0.034), but no changes were observed in the CG. There was no significant change in LDL cholesterol in both groups, but significantly more lipid-lowering therapy was administered in the CG (P = 0.049). Conclusion: In My-3F, the preventive benefit on CVRF (cardiovascular risk factors) and fitness of football training in patients after MI or CAD was clearly demonstrated for the first time. The concept proved to be safe and cost-effective and could open the doors of football clubs to evidence-based cardiological prevention.

Background: The 3F study (Fit&Fun with Football) demonstrated a significant reduction in blood pressure, antihypertensive medication, body weight, stress and depression through health football. Health football could be a popular tool to unleash the full preventive potential of physical activity. This work analyses the effect of health football on hypertensive subgroups: dipper, nondipper, white-coat hypertension (WCH), sustained hypertension, (un)treated hypertensive patients (UH, TH). Methods: A prospective interventional study with 1-year follow-up. Football group (FG): n = 103, ‘health’-football training (1×/week, 90 min) led by licensed football coaches. Physical inactive, hypertensive patients older than 45 years were compared with a control group (CG) (n = 105). Subgroups were divided by ambulatory blood pressure monitoring (ABPM), casual blood pressure (CBP), medication schedule and compared by blood pressure (BP), laboratory results and weight. Results: In all three subgroups (WCH vs. sustained hypertension, TH vs. UH, D vs. ND), health football reduced BP and weight significantly compared with the CG, and compared with the admission. An even greater effect in CBP was found in people with WCH than in sustained hypertension (FG: WCH: 141–127 mmHg, sustained Hypertension (SH): 142–132 mmHg; CG: WCH: 141–143 mmHg, SH: 140–141 mmHg). In contrast, the significant reduction in CBP and ABPM was comparable in treated and untreated patients, although antihypertensive drugs were reduced significantly more frequently in FG than in CG. BP reduction in nondippers and dippers was also comparable. In the nondipper group, nocturnal BP was significantly reduced in the FB (122.0–111.5 mmHg), but not in the CG or the dippers. Conclusion: All evaluated football subgroups achieved a significant BP reduction (compared with CG). This applied to dipper, nondipper, (un)treated hypertension, WCH and SH. All mentioned subgroups displayed a clear benefit. The even greater reduction in BP in WCH demonstrates the importance of physical activity before the additional prescription of antihypertensive medications, underscoring the recommendations of the ESC and ISH in WCH.

Introduction: It is well documented that insufficient physical activity (PA) contributes substantially to cardiovascular diseases. The number of physically active people in Germany is still too low. Methods: In ELITE study in Germany, 4602 participants are regularly examined for cardiovascular risk factors (CVRF). The aim is to motivate participants to improve their CVRF through individual recommendations and regular follow-up. Here, the PA data are presented in correlation with CVRF at baseline. A feature of this presentation is that the usual CVRF but also the effects on psychosocial factors were recorded simultaneously. Results: Participants were divided into 3 groups based on their PA: 1. frequent exercise (FE): daily to 2– 3x per week (41.4%), 2. moderate exercise (ME): 1x/week to 2x/month (28.8%), 3. rarely exercise (RE): 1x/month to not at all (29.8%). Age did not differ in the 3 groups. The most common CVRF was arterial hypertension, which decreased significantly with an increase in PA. Diabetes, nicotine, and increased BMI were also significantly less frequent in group 1. Antihypertensives were taken less frequently in this group 1. Less physically active participants were significantly more likely to have 3 or more additional CVRF. While group 1 consumed more fruit (64%) and considerably less pork, in group 2 and 3 only 58.3% and 50.3% respectively included fruit in their diet. FE also had a favorable effect on stress, depression and general well-being, all of which were significantly better in group 1. Conclusion: Results confirm the beneficial influences of exercise on known CVRF and on psychosocial parameters. The prevalence of several CVRF per person at low levels of sport is of particular concern, as these participants would benefit most. During a 5-year follow-up, participants will receive intensive education on the need to increase PA. It remains to be seen how successful the effort will be.

Lipoprotein(a) (Lp(a)) is becoming increasingly important as an independent risk factor for cardiovascular disease. Since no effective therapy currently exists other than lipid apheresis, the recommendation remains to optimally adjust all other cardiovascular risk factors (CVRF). In a Northwest German population study, the frequency of elevated Lp(a) levels and all other CVRF was investigated. The aim was to investigate whether individuals with elevated Lp(a) levels were also more likely to have other CVRFs. To date, 4602 individuals have been enrolled in the study, and blood pressure, weight, lipids, diabetes, medications, and pre-existing conditions were recorded in addition to Lp(a). In addition, questionnaires assessed physical activity, psychological stress, depression, and brain dysfunction. All participants received detailed individual recommendation about their CVRF and its treatment. In the further follow-up of 5 years, it will be examined how persons with elevated Lp(a) implemented these recommendations in comparison with participants without elevated Lp(a). The first group Lp(a) 120 nmol/L of 538 (11.7%). 81.6% of all participants had one or more CVRF. Age, sex, and prevalence of hypertension, diabetes, smoking, obesity, and exercise did not differ among the 3 groups. As expected, LDL-Cholesterol was significantly elevated in the Lp(a) >120 nmol/L group despite significantly more frequent use of statins. Significantly more often hypertensive patients were found in the Lp(a) >120 nmol/L group who were inadequately controlled by medication and significantly less often persons without further CVRF. No differences existed in the frequency of psychological stress, depression, and mild cognitive impairment. CVRF occur with comparable frequency in individuals with elevated Lp(a) levels. However, individuals with Lp(a) above 120 nmol/L were more likely to have poorly controlled blood pressure, elevated LDL-C, and less likely to have no other risk factors. This underlines that in case of Lp(a) elevation all further CVRF should be intensively adjusted, especially in case of strongly elevated values >120 nmol/L. However, these recommendations have not been adequately implemented in clinical care in this population to date.